Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluoxetine 60 mg Clear all
Completed Phase 1Phase 2 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00296725
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
Interventions
Fluoxetine, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression

NCT00787501
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

NCT00834834
View directory record Official record
Conditions
Borderline Personality Disorder, Suicide
Interventions
Fluoxetine, DBT, Citalopram
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 22, 2026, 1:48 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

NCT06698848
View directory record Official record
Conditions
Depression, Suicide
Interventions
ketamin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Hypochondriasis With CBT and/or SSRI

NCT00339079
View directory record Official record
Conditions
Hypochondriasis
Interventions
Fluoxetine, Cognitive Behavioral Therapy (CBT), Supportive Therapy, Placebo
Drug · Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

NCT00533117
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia

NCT00115804
View directory record Official record
Conditions
Juvenile Primary Fibromyalgia Syndrome (JPFS), Fibromyalgia
Interventions
Fluoxetine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 22, 2026, 1:48 PM EDT
Active, not recruiting Early Phase 1 Interventional

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707
View directory record Official record
Conditions
Primary Brain Tumor, Brain Tumor, Recurrent
Interventions
Fluoxetine, Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
24 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Diego, California • Stanford, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 22, 2026, 1:48 PM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial

NCT03638908
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Fluoxetine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 22, 2026, 1:48 PM EDT
Not listed Phase 4 Interventional

Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure

NCT00633685
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Combat-related
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
TEMPVA Research Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder

NCT00078754
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Fluoxetine, Divalproex, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

NCT01672255
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
Interventions
Fluoxetine, Placebo control
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

NCT01243957
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 22, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

NCT00758966
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg, Naltrexone SR 32 mg
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
National City, California • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 22, 2026, 1:48 PM EDT
Withdrawn Early Phase 1 Interventional

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

NCT04570449
View directory record Official record
Conditions
Covid19
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment in Elderly With Dysthymia

NCT01852383
View directory record Official record
Conditions
Depression, Dysthymic Disorder
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 22, 2026, 1:48 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

NCT05948553
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 22, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

NCT04377308
View directory record Official record
Conditions
COVID-19, Cytokine Storm
Interventions
Fluoxetine
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 22, 2026, 1:48 PM EDT